Cannabinoids for Postoperative Pain: A Systematic Review Finds Too Little Evidence to Draw Firm Conclusions

Only five eligible randomized controlled trials were identified across the entire published literature, their methods were too heterogeneous to pool statistically, and their results were contradictory, leaving the clinical question of whether cannabinoids meaningfully relieve acute postoperative pain effectively unanswered.

Why This Matters

Acute postoperative pain remains widely undertreated, and the well-documented harms of perioperative opioid exposure have intensified clinical interest in alternative analgesic strategies. Cannabinoids, increasingly accessible through shifting regulatory landscapes, are among the most frequently proposed candidates for opioid-sparing roles. Yet the gap between patient and provider enthusiasm and the actual trial evidence base has never been formally characterized for the acute surgical setting. This review arrives at a moment when that gap demands honest accounting before clinical practice outpaces the science.

Clinical Summary

Endocannabinoid system receptors, particularly CB1 and CB2, are distributed throughout peripheral nociceptive pathways, the spinal cord dorsal horn, and supraspinal pain-modulating circuits, providing a biologically plausible rationale for cannabinoid analgesia. A team led by researchers at Universidad El Bosque, publishing in the European Journal of Pain in 2025, conducted a systematic review registered under Cochrane and PRISMA methodology to determine whether randomized controlled trial evidence supports cannabinoid use for acute postoperative pain. They searched PubMed, Embase, Cochrane, Lilacs, and secondary databases without language or date restrictions, screening 62 articles and ultimately including only five RCTs that met their prespecified criteria for population, intervention, comparator, and outcome.

Across those five trials, results on pain intensity, rescue analgesic consumption, and adverse events were contradictory, with no consistent direction of effect favoring or disfavoring cannabinoids. Sixty percent of the included studies were rated low risk of bias, yet the methodological heterogeneity across studies, encompassing differences in cannabinoid type, dose, timing, surgical context, and outcome measurement, was sufficient to preclude any quantitative pooling. The authors make no clinical recommendation for or against cannabinoid use in this setting. They frame their primary contribution as a structured identification of the evidence gap itself and a set of methodological recommendations intended to guide the design of larger, more standardized future trials.

Dr. Caplan’s Take

This review does something genuinely useful: it tells us, in a rigorous and transparent way, that we do not actually know what we think we know about cannabinoids after surgery. Patients ask about this regularly, often citing media coverage or dispensary recommendations as though clinical efficacy were established fact. What an honest response requires is exactly what this paper provides: an acknowledgment that only five qualifying trials exist worldwide, that they disagree with each other, and that the question remains scientifically open. The mechanistic rationale is real, but rationale is not evidence.

In practice, I do not recommend cannabinoids as postoperative analgesics. There is not enough data to know whether they help, how much they help, which formulations matter, or what adverse event profile to expect in surgical patients who may also be receiving sedatives, antiemetics, and other CNS-active agents. What I do is have a candid conversation, explain the evidence gap, and ensure that multimodal analgesia with well-studied agents is optimized. When patients are already using cannabis products, I document it, watch for interactions, and avoid pretending the absence of evidence constitutes evidence of safety.

Clinical Perspective

This review sits at the earliest stage of the research arc for cannabinoids in acute surgical pain. It confirms that the preclinical rationale involving CB1 and CB2 receptor engagement in nociceptive pathways has not yet been translated into a coherent clinical evidence base. It does not confirm efficacy, refute efficacy, or establish a safety profile specific to the perioperative population. Clinicians should understand that the five included trials varied in cannabinoid formulation, dosing schedule, surgical type, and outcome definitions to a degree that made even directional conclusions impossible. Patient-facing recommendations claiming cannabinoids reduce postoperative pain or opioid requirements are not currently supported by the trial literature.

From a pharmacological standpoint, cannabinoids carry CNS-depressant properties that overlap with opioids, benzodiazepines, and anesthetic agents commonly used perioperatively. Drug interaction data in the acute surgical context are sparse. THC-containing formulations may exacerbate postoperative nausea and vomiting or cognitive dysfunction in susceptible patients, while CBD formulations may interact with hepatically metabolized drugs through cytochrome P450 inhibition. The single most actionable step clinicians can take now is to systematically document preoperative cannabinoid use in surgical patients, flag potential interactions with perioperative medications, and resist extrapolating chronic pain cannabinoid data into the acute postoperative setting.

Study at a Glance

Study Type

Systematic review (qualitative synthesis only; no meta-analysis performed despite title)

Population

Adult surgical patients experiencing acute postoperative pain

Intervention

Cannabinoid-based medicines (various formulations across included trials)

Comparator

Placebo or conventional analgesics

Primary Outcomes

Pain intensity (VAS), rescue analgesic use and dose, adverse events

Sample Size

5 RCTs included from 62 screened articles

Journal

European Journal of Pain

Year

2025

DOI or PMID

Not available in extracted data

Funding Source

Universidad El Bosque internal research fund

What Kind of Evidence Is This

This is a qualitative systematic review of randomized controlled trials, conducted under Cochrane and PRISMA methodology. Although the paper’s title includes the term “meta-analysis,” the authors explicitly state that no quantitative pooling was performed because methodological heterogeneity across the five included studies made statistical synthesis inappropriate. Its position in the evidence hierarchy is therefore that of a structured narrative synthesis rather than a pooled quantitative analysis. The most important inference constraint is that no summary effect estimate exists, meaning no magnitude or direction of cannabinoid effect on postoperative pain can be cited from this work.

How This Fits With the Broader Literature

The broader cannabinoid analgesia literature is dominated by chronic pain studies, where systematic reviews such as those by Whiting and colleagues (2015) and Aviram and Samuelly-Leichtag (2017) have reported modest analgesic effects with significant heterogeneity and adverse event burden. This review demonstrates that the acute postoperative pain question has been studied far less rigorously and cannot borrow conclusions from the chronic pain literature given the distinct pharmacological context, patient physiology, and concurrent medication exposure. The finding that only five qualifying RCTs exist globally for this specific indication underscores how far behind the clinical evidence lags relative to public and regulatory momentum around cannabinoid therapeutics.

Common Misreadings

The most likely overinterpretation is treating this review as evidence that cannabinoids do not work for postoperative pain. The review does not establish inefficacy. It establishes that the evidence is insufficient to determine efficacy in either direction. A related misreading involves the title’s inclusion of “meta-analysis,” which may lead readers to assume that pooled effect estimates were generated. No such pooling occurred, and citing this paper as a meta-analytic finding would misrepresent its actual methodology and conclusions. The absence of a detectable signal here is a property of the evidence base, not a property of the intervention.

Bottom Line

This systematic review confirms that the randomized trial evidence for cannabinoids in acute postoperative pain is nearly nonexistent: five small, heterogeneous, contradictory trials that cannot be pooled or summarized quantitatively. It neither supports nor refutes cannabinoid efficacy in this setting. Its value lies in documenting the evidence gap with methodological rigor and providing a framework for the larger, better-designed trials that must be completed before any clinical recommendation can be responsibly made.

References

1. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456-2473. doi:10.1001/jama.2015.6358
2. Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20(6):E755-E796. PMID:28934780
3. Universidad El Bosque research team. Cannabinoids for acute postoperative pain: a systematic review and meta-analysis. European Journal of Pain. 2025. (Specific DOI not available in extracted source data.)